# BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

> **NCT04196530** · PHASE1 · COMPLETED · sponsor: **Eikon Therapeutics** · enrollment: 40 (actual)

## Conditions studied

- Tumor, Solid

## Interventions

- **DRUG:** BDB001 (EIK1001)
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04196530
- **Lead sponsor:** Eikon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-21
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-08-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196530, "BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04196530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*